Results 1 to 10 of about 50 (49)
Nature Reviews Drug Discovery, 2010 n ...
Rizzoli R., Yasothan U., Kirkpatrick P.
openaire +5 more sources
mAbs, 2009 Denosumab is an anti-receptor activator of nuclear factor (NF)-kappaB (RANK) ligand human monoclonal antibody studied as a treatment for postmenopausal osteoporosis (PMO) and bone destruction due to rheumatoid arthritis (RA) or metastatic cancers. As of February 2009, the candidate was undergoing US Food and Drug Administration review, and might be ...
openaire +2 more sources
Denosumab for the treatment of osteoporosis [PDF]
Expert Opinion on Drug Metabolism & Toxicology, 2015 Low trauma fractures due to osteoporosis are a major health concern worldwide. Despite the availability of many therapeutic compounds to reduce fracture risk, osteoporosis remains undertreated and the burden of osteoporotic fractures remains high. Denosumab is a novel agent that acts to reduce bone turnover, improve bone mineral density, and reduce ...
Meryl S. LeBoff +2 more
openaire +3 more sources
Journal of Pain and Symptom Management, 2018 Therapeutic Reviews aim to provide essential independent information for health professionals about drugs used in palliative and hospice care. Additional content is available on www.palliativedrugs.com. Country-specific books (Hospice and Palliative Care Formulary USA, and Palliative Care Formulary, British and Canadian editions) are also available and
Rahul Girish +5 more
openaire +3 more sources
Denosumab for the Treatment of Osteoporosis [PDF]
Osteoporosis and Sarcopenia, 2013 Denosumab, a specific inhibitor of RANK ligand, is a novel therapy for postmenopausal osteoporosis and related disorders. An extensive clinical development program has evaluated the clinical efficacy and safety of denosumab with several thousand patients being followed for up to 10 years.
openaire +7 more sources
Qanun Medika - Medical Journal Faculty of Medicine Muhammadiyah Surabaya, 2019 ABSTRACT Osteoporosis is one of the most common chronic diseases. This condition makes bones in a person to become more porous and fragile, therefore greatly increase their risk of suffering a fracture. In Asia, the mortality rate that are associated with these fractures occurred between 10–20% of cases within a year.
Raditya Pria Utama, Hesty Rohmatul Fajri
openaire +2 more sources
Denosumab-Induced Immune Hepatitis [PDF]
Biomedicines, 2021 Denosumab–Prolia®, Xgeva® (Amgen) is a fully human antibody to the receptor activator of the nuclear factor-K ligand (RANKL). Hepatotoxicity is extremely rare, with only one reported case of immune origin. We present a second case of hepatotoxicity resulting from an immune reaction to denosumab.
Ostrovsky, Viviana +5 more
openaire +4 more sources
Denosumab: A comprehensive review
South Asian Journal of Cancer, 2013 AbstractThe clinical sequelae from bone metastases, termed skeletal-related events (SREs), are among the most frequent and debilitating complications in patients with advanced cancer. Bone metastases are characterized by pathologically increased osteoclast activity, and accumulating evidence indicates that tumor cells interact within the bone to ...
openaire +4 more sources
A review of denosumab for the treatment of osteoporosis
Patient Preference and Adherence, 2014 Osteoporosis is an age-related systemic skeletal disease characterized by low bone mass and microarchitectural deterioration of bone tissue, with a consequent increase in bone fragility. Bone remodeling involves two types of cells: osteoblasts and osteoclasts.
Sakae Tanaka +2 more
openaire +6 more sources
Osteonecrosis of the Jaw in a Patient on Denosumab [PDF]
Journal of Oral and Maxillofacial Surgery, 2010 Osteonecrosis of the jaws (ONJ) clinically presents as exposed, necrotic bone in the maxilla or mandible of at least eight week duration, with or without the presence of pain, infection, or previous trauma in a patient who has not received radiation to the jaws (1–3).
Sotirios Tetradis +2 more
openaire +3 more sources